Then, tau tracer could be used to describe the spatiotemporal pattern of tau deposition in AD patients, which had been replicated by tau-PET imaging studies in vivo (Koychev et al., 2017; Baghel et al., 2019; Das et al., 2019; Zhao et al., 2019; Cho et al., 2020; Hsu et al., 2021; Seemiller et al., 2021). This evidence concerns the gene MAPT and Alzheimer disease.